Menu
Not yet recruiting NCT07343570

Comparison of Quadratus Lumborum and Combined Groin Nerve Blocks for Postoperative Analgesia After Open Inguinal Hernia Repair.

Phase III Interventional Postoperative Analgesia of Inguinal Hernia Repair in Adults

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Ultrasound-guided lateral quadratus lumborum block, Combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block.
Who it may be relevant to
Registry conditions: Postoperative Analgesia of Inguinal Hernia Repair in Adults. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Comparing Ultrasound-guided Lateral Quadratus Lumborum Block Versus Combined Ilio-inguinal/Ilio-hypogastric /Genitofemoral Block for Postoperative Analgesia After Open Inguinal Hernia Repair: A Double-blind Randomized Controlled Trial

Overview

This double-blind randomized controlled trial aimes to compares two ultrasound-guided regional techniques-lateral quadratus lumborum block versus combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block-for postoperative analgesia after elective unilateral open inguinal hernia repair under spinal anesthesia in adults.

Interventions

  • Procedure Ultrasound-guided lateral quadratus lumborum block
    Ultrasound-guided lateral quadratus lumborum block. Local anesthetic: 30 ml of (Ropivacaine 0.2%) is injected at the appropriate fascial level.
  • Procedure Combined ilio-inguinal/ilio-hypogastric/genitofemoral (II-IH-GFN) block
    Ultrasound-guided ilio-inguinal and ilio-hypogastric block. Local anesthesia: 20 ml of 0.2% ropivacaine for ilio-inguinal and ilio-hypogastric block + 10 ml of 0.2% ropivacaine for genitofemoral anaesthesia, total injection volume = 30 ml.

Primary outcome measures

  • Cumulative opioid consumption in the first 24 hours postoperatively [Time frame: 24 hours after surgery.]
Secondary outcome measures (8)
  • Pain intensity (VAS pain scores at rest ) [Time frame: 24 hours postoperatively.]
  • Pain intensity (VAS pain scores at movement) [Time frame: 24 hours postoperatively.]
  • Time to first analgesic request [Time frame: 24 hours.]
  • Proportion of patients requiring rescue opioid analgesia [Time frame: 24 hours.]
  • Incidence of postoperative block-related complications [Time frame: 24 hours.]
  • Patient satisfaction score [Time frame: Assessed at 24 hours postoperatively.]
  • Post-anesthesia care unit (PACU) stay duration [Time frame: 24 hours]
  • Total hospital stay duration [Time frame: 24 hours]

Eligibility criteria

Inclusion criteria

  • Adults aged 18-75 years.
  • ASA physical status I-III.
  • Scheduled for elective unilateral open inguinal hernia repair under standardized spinal anesthesia.
  • Able to understand and use the Visual Analogue Scale (VAS).
  • Provided written informed consent.

Exclusion criteria

  • Allergy to local anesthetics.
  • Coagulopathy or current use of anticoagulants contraindicating peripheral nerve blocks.
  • Infection at the injection site.
  • Chronic opioid use (daily opioids >2 weeks) or chronic pain syndromes.
  • Body mass index (BMI) >40 kg/m².
  • Conversion to other surgery or bilateral repair.
  • Pregnant patients.
  • Refusal to sign informed consent.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Al Azhar University — Cairo

Identifiers

NCT: NCT07343570 · RC. 12.9.2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗